What is the standard of care for early stage Pancreatic Cancer according to NCCN guidelines

Standard of Care for Early-Stage Pancreatic Cancer (NCCN Guidelines)

Based on the NCCN Guidelines for Pancreatic Adenocarcinoma (Version 2.2025), the standard of care for early-stage pancreatic cancer depends on whether the tumor is resectable (surgically removable) or borderline resectable.

For Resectable Disease

According to NCCN Guidelines, the primary treatment approach includes:

Surgery as the foundation:

• Surgical resection (removal) is the main treatment goal for resectable tumors
• This may be performed via traditional open surgery (laparotomy) or minimally invasive approaches
• Staging laparoscopy may be considered to evaluate for distant disease before committing to major surgery

Neoadjuvant therapy (treatment before surgery):

• NCCN Guidelines now recommend considering neoadjuvant therapy (chemotherapy given before surgery) for patients with high-risk features
• High-risk features include: equivocal imaging findings, markedly elevated CA 19-9 (a tumor marker), large primary tumors, large regional lymph nodes, significant weight loss, or severe pain
• Neoadjuvant therapy typically lasts 4-6 months before surgery

Adjuvant therapy (treatment after surgery):

• After successful surgical resection, patients receive adjuvant chemotherapy to eliminate any remaining cancer cells
• Total duration of systemic therapy is typically around 6 months
• Chemotherapy may be followed by chemoradiation (chemotherapy combined with radiation therapy) as clinically indicated

Important Diagnostic Steps Before Treatment

Before starting treatment, NCCN Guidelines emphasize:

1. Genetic testing - Recommended for all pancreatic cancer patients to identify inherited mutations (BRCA1/2, PALB2, ATM, and others)
2. Molecular profiling - Tumor tissue testing to identify actionable mutations that may guide targeted therapy options
3. Complete staging - Chest and pelvis CT imaging to rule out metastatic disease
4. Multidisciplinary consultation - Evaluation at a high-volume cancer center involving surgery, medical oncology, radiation oncology, and other specialists

Key Point: Precision Medicine Approach

As emphasized in the NCCN Guidelines, the modern standard of care is moving beyond "one-size-fits-all" treatment. According to Dr. [removed] Strickler's insights from the Cancer Patient Lab webinar on "Navigating Pancreatic Cancer," every pancreatic cancer patient should ask their doctor: "Have you done molecular profiling on my cancer? Can I see the report?" This information is now part of the national guidelines and can identify patients eligible for targeted therapies beyond traditional chemotherapy.

Questions to Ask Your Oncology Team

1. Is my tumor resectable, borderline resectable, or locally advanced based on imaging?
2. Do you recommend neoadjuvant therapy before surgery, and if so, which chemotherapy regimen?
3. Has molecular profiling been performed on my tumor tissue? What mutations were found?
4. Have I been tested for inherited genetic mutations (germline testing)?
5. What is the planned adjuvant therapy after surgery, and how long will treatment last?
6. Are there clinical trials available that match my specific tumor profile?
7. Will my care be coordinated at a high-volume pancreatic cancer center?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.